Praxis Precision Medicines (PRAX) Misses Q3 EPS by 76c

Praxis Precision Medicines (NASDAQ: PRAX) reported Q3 EPS of ($2.75), $0.76 worse than the analyst estimate of ($1.99). Revenue for the quarter came in at $302 thousand versus the consensus estimate of $328.56 thousand.

For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.

You May Also Be Interested In

• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Anterix Inc. (ATEX) Tops Q4 EPS by 152c
• Global Net Lease (GNL) Reiterated at Market Outperform by Citizens Amid De-leveraging